adagrasib

  •   George Lundberg, MD

    As reported by The ASCO Post, the drug adagrasib has shown some promising results in a clinical trial for people with advanced non-small cell lung cancer (NSCLC) with a KRAS-g12c mutation whose cancer progressed after prior treatment. The U.S. Food and Drug Administration (FDA) allows adagrasib to be given to people whose cancer has a KRAS-g12c mutation through expanded access.

    .